sofetabart

Sofetabart (LY3538015) is a folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC) developed by Eli Lilly. It consists of a humanized IgG1 monoclonal antibody directed against FRα, which is highly expressed in various solid tumors, particularly ovarian cancer. The antibody is conjugated via a protease-cleavable linker to a potent topoisomerase I inhibitor payload, specifically an exatecan derivative. Upon binding to FRα on the surface of tumor cells, the ADC is internalized through endocytosis, and the payload is released within the lysosomal compartment. The released topoisomerase I inhibitor then induces DNA double-strand breaks, leading to cell cycle arrest and apoptosis. Sofetabart is currently being evaluated in Phase 3 clinical trials for the treatment of both platinum-resistant and platinum-sensitive ovarian cancer.

Other names

sofetabartFRα-targeted ADC